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Abstract: Despite the availability of predictive tools and treatment
guidelines, anticoagulant therapies are underprescribed and many
patients are undertreated for conditions that predispose to thromboem-
bolic complications, including stroke. This review explores reasons for
which physicians fear that the risks of anticoagulation may be greater
than the potential beneﬁt. The results of numerous clinical trials conﬁrm
that patients beneﬁt from judiciously managed anticoagulation and that
physicians can take various approaches to minimize risk. Use of
stratiﬁcation scores for patient selection and accurate estimation of
stroke risk may improve outcomes; bleeding risk is less important than
stroke risk. Adoption of newer anticoagulants with simpler regimens
may help physicians allay their fears of anticoagulant use in patients
with atrial ﬁbrillation. These fears, although not groundless, should
not overtake caution and hinder the delivery of appropriate evidence-
based care.
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THE LANDSCAPE: ANTICOAGULATION
INDICATIONS AND USE
A trial ﬁbrillation (AF) is the most common cardiac arrhyth-mia, affecting approximately 2.4 million Americans and
predisposing to a risk for ischemic stroke that is 2 to 5 times
greater than that of age-matched controls.1–3 Stroke is the lead-
ing cause of adult disability, affecting 795,000 Americans
annually.4 An estimated 69,165 of these strokes are attributable
to AF.5,6 Every hour, approximately 8 Americans suffer from an
ischemic stroke arising from AF.5,6 Currently, validated risk
stratiﬁcation schemes such as CHADS2 and CHA2DS2-VASc,
based on other predisposing conditions, facilitate stroke predic-
tion in patients with AF (Table 1).7,8 Oral anticoagulation can
make a signiﬁcant dent in this stroke risk in AF and is backed
by evidence-based stroke prevention guidelines.8–10 Recently,
schemes such as HAS-BLED (Table 2) have been developed to
evaluate the risk of bleeding, the feared complication of oral
anticoagulation therapy.11–13 Despite guidelines and tools, anti-
coagulation is underprescribed, which exposes patients with AF
to the risk of debilitating strokes.3
Several studies have evaluated the prevalence of oral
anticoagulation use in patients with AF.14–20 The rate of oral anti-
coagulation prescribing in patients with AF with a moderate-to-
high risk of stroke ranged from 41% to 65%.14,21,22 Even after the
elimination of patients with contraindications to anticoagulation,
the rate of oral anticoagulation use did not increase.14,21,22 Among
these studies, the National Anticoagulation Benchmark Out-
comes Report (NABOR), a performance improvement program,
investigated treatment gaps and predictors of warfarin use in
a nationally representative AF population sample in the United
States.14 Although risk factors indicated that 86% of patients had
a high risk for stroke, only 55% of those at high risk received
warfarin.14 High-risk stratiﬁcation was not a positive predictor for
warfarin use, and contraindications to warfarin did not account
for the marked level of underuse.14 Another study examined
Medicare Part D claims data for warfarin use among beneﬁciaries
with nonvalvular AF (NVAF) in the context of current treatment
guidelines.21 Among those at moderate-to-high stroke risk but not
at high bleeding risk, 41.3% did not receive warfarin within
12 months of the index diagnosis.21 These real-world results
showed that a signiﬁcant proportion of Medicare beneﬁciaries
in need of anticoagulation were not treated according to clinical
guidelines, which led to an excessive rate of ischemic stroke in an
at-risk population.21
The underuse of warfarin may stem from the drug’s well-
known limitations; however, compliance with guidelines may also
be inﬂuenced by variables at system, physician, and patient lev-
els.22 Newer oral anticoagulants may reduce the risk of stroke with
a lower risk of adverse events than warfarin, but the need to
understand why physicians deviate from anticoagulation guide-
lines “has implications that transcend therapeutic class.”22 This
review explores possible explanations for withholding anticoagu-
lant therapy. Such explanations frequently are based on fears that
the risks are greater than any potential beneﬁt of anticoagulants.23
Although it is undeniable that anticoagulant therapy may be asso-
ciated with risk of bleeding, it is also evident from long experience,
conﬁrmed by objective analysis, that patients beneﬁt from anti-
coagulation and that there are ways to minimize their bleeding risk.
The choice of new oral anticoagulants with different mechanisms
of action and simpler regimens may help persuade physicians and
patients alike. It should be noted that the majority of studies to date
with newer oral anticoagulants have focused on stroke risk factors
in patients with NVAF. Although not as common, patients with
valvular AF (VAF, ie, those with AF and rheumatic mitral stenosis
or a prosthetic mitral valve) are also at risk for ischemic stroke.24
Although warfarin therapy (based on target International normal-
ized ratio [INR]) has been reported as an effective means for stroke
prevention,8 the role that newer anticoagulants might play in stroke
prevention in patients with VAF has not been evaluated.
BARRIERS TO ADEQUATE ANTICOAGULATION:
REAL AND PERCEIVED REASONS
FOR UNDERTREATMENT
Physicians’ Fears
Many physicians associate anticoagulant use with
a heightened risk of bleeding.25 Death certiﬁcate data in 2003
and 2004 ranked anticoagulants ﬁrst in the number of mentions
of “deaths from drugs causing adverse effects in therapeutic
use.”26 For a retrospective analysis of health care claims within
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a 4 million member managed care organization, patients diag-
nosed with AF were stratiﬁed into 2 cohorts: warfarin therapy
(patients initiating warfarin) or warfarin candidates (eligible
according to American College of Cardiology/American Heart
Association/European Society of Cardiology guidelines but not
receiving warfarin).27 During 2 years of follow-up, 4.7% expe-
rienced a hemorrhagic event.27 The incidence of intracranial
hemorrhage was identical in both cohorts.27 There was no sig-
niﬁcant increase in risk for hemorrhage within the warfarin
therapy group after adjustment for age, sex, and additional risk
factors for hemorrhage.27 Although the study was not designed
to determine why warfarin was underused despite indications
for its use, the perceived risk of bleeding complications may
have been a contributing factor.27 The investigators acknowl-
edged that use of nonprescription antiplatelet agents may have
contributed to the similarity in rates of hemorrhage and sug-
gested that such similarity might also have resulted from con-
servative dosing and management of warfarin therapy, possibly
with attainment of a lower INR than achieved in clinical trials.27
Earlier investigators noted that physicians treating patients with
AF were more averse to cause harm in the form of warfarin-
related hemorrhage than harm due to stroke resulting from fail-
ure to treat with warfarin.28 If physicians’ treatment decisions
are driven predominantly by historical concerns regarding an
increased bleeding risk, conservative use and cautious dosing
may deprive patients of the full beneﬁt of anticoagulation.27
An Australian group randomly selected 1,000 family
physicians, of whom 596 responded to a survey aimed at
TABLE 1. Risk scores to stratify candidates for anticoagulant therapy7,8
CHADS2 risk criteria Value CHADS2 score Adjusted stroke risk (%/yr)
Congestive heart failure 1 0 1.9
Hypertension 1 1 2.8
Age $75 yr 1 2 4.0
Diabetes 1 3 5.9
Stroke/TIA/TE 2 4 8.5
5 12.5
Maximum 6 6 18.2
CHA2DS2-VASC risk criteria Value CHA2DS2-VASC score Adjusted stroke risk (%/yr)
Congestive heart failure/LV dysfunction 1 0 0
Hypertension 1 1 0.7
Age $75 yr 2 2 1.9
Diabetes 1 3 4.7
Stroke/TIA/TE 2 4 2.3
Vascular disease (prior MI, PAD and aortic plaque) 1
Age, 65–74 yr 1 5 3.9
Sex, female 1 6 4.5
Maximum 9 7 10.1
8 14.2
9 100.0
LV, left ventricular; MI, myocardial infarction; PAD, peripheral arterial disease; TE, thromboembolism; TIA, transient ischemic attack.
TABLE 2. Clinical criteria for HAS-BLED bleeding risk score
Clinical criteriaa Score HAS-BLED score Bleeds/100 patient-yrb
Hypertension 1 0 1.13
Abnormal renal or liver function (1 pt each) 1 or 2 1 1.02
Stroke 1 2 1.88
Bleeding 1 3 3.74
Labile INR 1 4 8.70
Elderly 1
Drug or alcohol use (1 pt each) 1 or 2
Maximum 9
a Hypertension: systolic blood pressure.160 mm Hg; abnormal renal function: chronic dialysis or renal transplantation or serum creatinine$200
mmol/L; abnormal liver function: chronic hepatic disease or biochemical evidence of signiﬁcant hepatic derangement (eg, bilirubin .2 times upper
limit of normal associated with liver enzymes.3 times upper limit of normal); bleeding: history of or predisposition to bleeding; labile INR: unstable/
high INR or poor time in therapeutic range; drug or alcohol use: concomitant use of antiplatelet agents or nonsteroidal anti-inﬂammatory drugs.
b Based on initial cohort reported by Pisters et al11 with insufﬁcient events at HAS-BLED score $5 to provide rates; actual stroke rates in
contemporary cohorts may vary from these estimates.
INR, international normalized ratio.
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identifying barriers to the use of anticoagulation.29 Offered
a choice of strategies for AF management, a minority (45.6%)
of respondents selected warfarin in the presence of a minor risk
for falls; even fewer (17.1%) said they would prescribe warfarin
for a patient receiving treatment for a peptic ulcer.29 Prescribing
patterns were inﬂuenced by physicians’ experience and fear of
bleeding events. For example, among the physicians surveyed,
15.8% reported having a patient with AF experience an intra-
cranial hemorrhage while on anticoagulation, whereas 45.8%
reported having patients who experienced ischemic stroke in the
absence of anticoagulant therapy.29 The experience of intracra-
nial hemorrhage in an anticoagulated patient with AF appeared
to condition family physicians to feel responsible for this out-
come, whereas they admitted to no such responsibility when
presented with the more common experience of stroke in
a patient with AF not receiving anticoagulation.29 The inculca-
tion to “ﬁrst do no harm” may condition physicians to feel more
responsible for harm resulting from “commission” rather than
“omission,” and this sense of culpability may lead them to shun
therapies they associate with a risk of adverse events, even
when the potential beneﬁts are shown to be greater than the
risks.29
Strikingly, similar results emerged from a population-
based matched-pair analysis of 530 Canadian physicians’
warfarin-prescribing patterns before and after adverse bleeding
events in patients with AF. Warfarin-associated bleeding events
negatively inﬂuenced warfarin prescribing throughout the 90-
day study, whereas adverse events possibly related to underuse
of warfarin seemed not to affect subsequent prescribing.30
Fear of bleeding is the factor common to clinicians
providing warfarin therapy across countries and continents.23,31–33
Warfarin anticoagulation to conventional intensities increases
the risk of intracranial hemorrhage 7- to 10-fold to an absolute
rate of 1% annually for many stroke-prone patients.33 Most
such hemorrhages (70%) are intracerebral hematomas, with
patient-related risk factors (advanced age, prior stroke, hyper-
tension and intensity of anticoagulation) overlapping those for
stroke.33 Although intracranial bleeding is the most feared
complication of anticoagulation, more common sites of bleed-
ing are in fact the gastrointestinal (GI) tract, the genitourinary
tract, and the soft tissues.34
After analyzing studies published between 1966 and
2002, Man-Son-Hing and Laupacis35 concluded that physi-
cians’ fears of the risk of bleeding associated with anticoagulant
therapy are often exaggerated and unfound. Studies pursued
when the intensity of anticoagulation was higher than current
levels (target INR 3.0–4.5 versus 2.0–3.0) showed higher than
expected rates of intracerebral hemorrhage in anticoagulated
patients with a history of stroke, whereas recent studies based
on the current less aggressive INR target have not conﬁrmed
those early ﬁndings.35 The salient issue is careful selection of
patients and accurate estimation of stroke risk; anticoagulant-
associated bleeding risk needs to be considered relevant to rel-
atively few patients.35
Specific Fears: Falling, Upper GI Tract Bleeding
and Stroke
Investigators and clinicians agree that there is an
increased risk of potentially life-threatening bleeding compli-
cations associated with anticoagulant therapy, including
bleeding into speciﬁc sites such as the GI tract or intracranial
bleeding in patients with head trauma or uncontrolled
hypertension.35 However, after a 1999 decision analysis,
Man-Son-Hing et al36 asserted that a predisposition to falling,
with the possibility of head trauma, is not a contraindication
to the use of anticoagulant therapy in older patients with AF.
They calculated that for the person with an average risk of AF-
related stroke, the 5% annual risk of subdural hematoma from
falling is so small that the person would have to fall 295 times
in the course of a year to accrue greater risk than beneﬁt from
anticoagulant therapy.36 Similarly, systematic review by Man-
Son-Hing and Laupacis35 demonstrated that in the era of routine
testing and treatment for Helicobacter pylori infection, patients
with a history of resolved upper GI tract bleeding seem to be at
no higher risk of upper GI bleeding than those with a negative
history.35
However, it should be noted that GI bleeding is one of
the feared complications of anticoagulant therapy in patients
who are frequently taking NSAIDs.37 Pooled results of a sys-
tematic analysis of 18 case-control and cohort studies per-
formed between 1990 and 1999 demonstrated that persons
taking nonsteroidal anti-inﬂammatory drugs (NSAIDs) without
cytoprotection had a relative risk (RR) of 3.8 (95% conﬁdence
interval [CI], 3.6–4.1) for GI tract bleeding.38 The increased risk
was maintained during treatment and returned to baseline on
cessation of treatment.38 Results of randomized comparative trials
showed that concomitant use of an NSAID with misoprostol or
a proton pump inhibitor reduced the upper GI bleeding risk by
approximately one half.39,40 Use of a cyclooxygenase-2 inhibitor-
speciﬁc NSAID reduced the risk of upper GI tract bleeding to
about half the rate associated with conventional NSAIDs.41 To
determine how factors that increase the risk of major upper GI
tract hemorrhage inﬂuence the choice of antithrombotic treatment
for older patients with AF and an elevated risk for stroke,
Man-Son-Hing and Laupacis42 conducted a systematic literature
search of studies published between January 1966 and December
2000 in developing a decision-analytic model based on the risk of
upper GI tract bleeding and stroke.42 The investigators deter-
mined the risk of anticoagulant-related bleeding in the presence
of deﬁned risk factors; that is, 3.8 times baseline for a patient
taking a noncytoprotective NSAID and 2.4 times baseline for
a patient taking warfarin, which resulted in a risk of 9.1 times
baseline (3.8 3 2.4) for a patient taking both medications.42
Across several clinical scenarios, anticoagulation was the best
therapy in terms of gain in quality-adjusted life-years for most
of the older patients with AF.42 The main exception was patients
with a low risk of AF-related stroke (because of an absence of
clinical risk factors for stroke) combined with a high risk of upper
GI tract bleeding (because of concomitant use of noncytoprotec-
tive NSAIDs).42 For such patients, acetylsalicylic acid (ASA) or
no antithrombotic therapy appeared appropriate.42 For older
patients with AF and a higher than average risk for upper GI
tract bleeding, the choice of antithrombotic therapy for stroke
prevention varied according to the magnitude of bleeding
risk.42 The authors concluded that warfarin was no longer
clearly the optimal antithrombotic therapy for older persons
with a signiﬁcantly higher risk of upper GI tract bleeding
and/or lower risk for stroke who were concurrently taking
a conventional NSAID.42
Lowering the Barriers to Effective Anticoagulation
In a 2011 editorial, Goldhaber43 addressed practical is-
sues confronting physicians who provided day-to-day care of
patients on anticoagulant therapy. Faced with a surfeit of infor-
mation, clinicians lack a “unifying and reliable” source of infor-
mation about developments in anticoagulant therapy.
Goldhaber noted, for instance, important differences among 3
apparently authoritative sets of practice guidelines.44–46 There
are also clinically important differences among various schemes
for stratifying stroke risk in patients with AF.43 Experts fail to
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agree which tool is the most reliable for scoring bleeding risk
during anticoagulant therapy.43 Not surprisingly, clinicians
are uncertain how to balance the risk of thromboembolic events
against the risk of bleeding and consequently, for fear of caus-
ing harm, err on the side of caution. Other stratiﬁcation schemes
are available that can help clinicians estimate patients’ who
fall risk and make better selection of candidates for anticoagu-
lation even when a risk for falls is present.47,48
A positive direction for future therapy emerged from
a study by Banerjee et al49 who modeled differing scenarios
using a real-world cohort derived from the Danish National
Patient Registry. In patients with a CHADS2 score $1 or
CHA2DS2-VASc score $2, warfarin offered a net clinical
beneﬁt in preventing stroke, but the newer Food and Drug
Administration (FDA)–approved agents, dabigatran, rivaroxa-
ban and apixaban, offered greater net clinical beneﬁt than
warfarin.49 The authors suggest that their ﬁndings may encour-
age physicians to use anticoagulation in patients stratiﬁed by
a relatively simple risk-scoring system (Figure 1) and raise
awareness of the advantages of a new generation of anticoagu-
lants compared with warfarin.49
Primary care physicians may overlook hypertension as
a powerful determinant of intracerebral hemorrhage risk,
whereas hypertensive patients are often unaware of symptoms
until they suffer a catastrophic complication, such as ischemic
stroke or intracerebral hemorrhage.34,50 Providing effective
antihypertensive therapy by the physician, and close adherence
to therapy by the patient, are essential to reduce the risk of
intracerebral hemorrhage associated with anticoagulation in pa-
tients with hypertension patients.34,50 Advances in neuroimag-
ing with magnetic resonance are allowing unprecedented
insights into brain pathology and predictive factors for intrace-
rebral hemorrhage risk, but such techniques are not yet fully
developed for routine clinical use.34,50 The impact of
FIGURE 1. Algorithm for choice of anticoagulant in patients with nonvalvular AF. Relative effectiveness based on post hoc modeling
using the Danish National Registry.47 AF, atrial fibrillation; ASA, acetylsalicylic acid; CHF, congestive heart failure; DM, diabetes mellitus;
HTN, hypertension; INR, international normalized ratio; NSAID, nonsteroidal anti-inflammatory drug; TIA, transient ischemic attack.
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hypertension control in reducing the incidence of intracerebral
hemorrhage has been demonstrated in a number of trials, notably
the Perindopril Protection against Recurrent Stroke Study (PROG-
RESS).51 In patients at high risk for recurrent stroke (N 5 6105,
mean age 64 years), absolute rates of intracerebral hemorrhage
dropped from 2% to 1% (RR reduction, 50%; 95% CI, 26–67),
when mean blood pressure was reduced by 12/5 mm Hg from
baseline.51
A history of stroke should not be considered a contrain-
dication to anticoagulant treatment: a prior stroke increases the
risk of another stroke for a patient with AF.35 For most patients,
nonfatal and extracranial bleeds are far less clinically signiﬁcant
than strokes of any severity, and patients at risk who are not
adequately anticoagulated may be more likely to have embolic
strokes.34,49 The American Hospital Association/American
Stroke Association’s 2012 science advisory on the use of oral
antithrombotic agents for stroke prevention in NVAF did not
directly address physicians’ fears regarding anticoagulation.52
However, in reiterating the FDA’s rationale for approving
a higher but not a lower dose of a new oral anticoagulant,
dabigatran etexilate, the advisory alluded to a prior observation
that “the irreversible effects of strokes and systemic emboli
have greater clinical signiﬁcance than nonfatal bleeding.”52–54
Superior stroke prevention with the higher dose, as the FDA’s
approval indicates, is a more desirable outcome than a lower
rate of nonfatal bleeding with the lower dose.53,54
A recent analysis of outcomes in a retrospective cohort
helps to illuminate the RRs, beneﬁts and optimal timing for
reinitiating warfarin therapy after a major gastrointestinal bleed-
ing (GIB) event.55 Anticoagulation therapy with warfarin was
reinitiated in 653/1,329 (49.1%) of the patients, which was asso-
ciated with a decreased risk of thromboembolism (hazard ratio
[HR], 0.71; and 95% CI, 0.54–0.93; P 5 0.01), and decreased
mortality (HR, 0.67; 95% CI, 0.56–0.81; P, 0.0001).55 Of note,
the recurrence rate of major GIB events was not affected by the
reinitiation of warfarin anticoagulation therapy, with an HR of
1.18 (95% CI, 0.94–1.10).55 Although limited by the retrospec-
tive design of this study, this analysis suggests that restarting
warfarin anticoagulant therapy 7 days or later after a major
GIB event is associated with lower rates of thromboembolism
and increased survival, with no increase in GIB event rates.55
Physicians may be hesitant to treat with anticoagulants if they
lack conﬁdence in the patient’s ability to adhere to a medication
regimen.35 The many challenges of warfarin use, a lengthy dose-
adjustment period, the need for frequent sampling and regular
anticoagulation monitoring, the difﬁculty of maintaining the INR
within the therapeutic range, dietary restrictions, raise barriers to
optimal anticoagulation in at-risk populations.25,32,34 The educa-
tional approach developed by Garcia et al25 for the Anticoagula-
tion Forum (Table 3) offers a comprehensive and practical
education model that may be adapted to encourage patients’
adherence in any therapeutic area.
Although treatment with the newer oral anticoagulants
is more expensive than with older therapy, such as warfarin,
these agents may offer adherence advantages because they have
simpler dosing regimens and fewer requirements for dose
adjustment, anticoagulation monitoring, or dietary restrictions.
Because there are no available reversal agents for these newer
therapies, patients and prescribers should be aware that optimal
protocols to address bleeding event complications are still under
development, whereas new and speciﬁc reversal therapies are
currently in clinical trials.56,57
Conventional Anticoagulation
Warfarin
Warfarin received FDA approval in 1954 and is the most
widely prescribed oral anticoagulant drug in North America.58,59
It induces anticoagulant activity by antagonizing vitamin
K-dependent synthesis of clotting factors in the liver.58 Although
the antiplatelet agent ASA has been found to reduce the risk of
stroke by 21%, long-term therapy with warfarin is associated
with a stroke risk reduction of 68%.60,61 Warfarin, slow to take
TABLE 3. Fifteen key points for patient education about oral anticoagulant therapy
1. Indicate the reason for initiating anticoagulant therapy and how it relates to clot formation
2. Review the names of the patient’s medications, both trade and generic names, explain why they are indicated and discuss how they work
for the purpose they are prescribed
3. Discuss how long therapy is likely to be needed
4. If the patient is taking warfarin, explain the importance of regular monitoring, target values and what the INR indicates
5. If the patient is taking warfarin, explain the importance of dietary precautions, including restrictions on alcohol and green leafy
vegetables
6. Describe common signs and symptoms of bleeding and what to do if they occur
7. Describe common signs and symptoms of clotting complications and what to do if they occur
8. Outline precautions the patient should take to minimize the risk of trauma or bleeding
9. Discuss potential drug interactions and how to manage medication changes
10. For women of child-bearing age, explain the importance of contraception
11. Explain the importance of informing all health care providers (eg, dentists, optometrists) of the use of anticoagulant medication
12. Emphasize the importance of notifying the anticoagulation provider when dental, surgical or other interventional procedures are
scheduled
13. Explain when and how to take anticoagulant medications and how to manage a missed dose
14. Discuss the utility of carrying identiﬁcation (identiﬁcation card, medical alert bracelet)
15. Document the education imparted to the patient
Adapted from Garcia et al, Delivery of optimized anticoagulant therapy: consensus statement from the Anticoagulation Forum. Ann Pharmacother
2008;42:979–88. Reprinted by Permission of SAGE Publications.25 Adaptations are themselves works protected by copyright. So in order to publish
this adaptation, authorization must be obtained both from the owner of the copyright in the original work and from the owner of copyright in the
translation or adaptation. Copyright © 2008 by SAGE Publications.
INR, international normalized ratio.
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effect and difﬁcult to dose, has been the only available oral
anticoagulant for the last half century.25,58,61 The response to
warfarin is subject to genetic variations and drug–drug interac-
tions,61,62 and the therapeutic effect is susceptible to dietary var-
iations,61 some of which, such as consumption of green and leafy
vegetables, might otherwise be considered positive behaviors for
stroke risk reduction. Warfarin is also a leading cause of emer-
gency department visits and preventable costs.63,64 The low
acquisition cost of warfarin may be counterbalanced by the
costs of laboratory monitoring to ensure that the anticoagu-
lant effect remains within the narrow safe range and by the
costs of managing potentially catastrophic complications of
therapy.64,65 Despite its shortcomings, warfarin remains an
important drug for long-term anticoagulant therapy world-
wide.66 An estimated 7 million people in the United States
and Europe have either paroxysmal or persistent AF, for
which anticoagulant therapy is indicated to reduce the risk
of stroke.66 However, the recent approval of new oral anti-
coagulants offers therapeutic alternatives that are at least as
effective as warfarin and offer a potential for safer and more
easily managed anticoagulation.67–71
New Oral Anticoagulants
Three new oral anticoagulants have recently been
approved in the United States for the reduction of stroke risk
in patients with AF: dabigatran, rivaroxaban and apixa-
ban.10,32,69–71 These agents have been compared with warfarin;
to date, head-to-head comparisons are lacking.32
Dabigatran Etexilate
Dabigatran etexilate, an oral direct thrombin inhibitor,
was approved by the FDA in 2010 to reduce the risk of stroke
and systemic embolism (SSE) in patients with NVAF.72,73
Dabigatran etexilate is administered in a ﬁxed dose of 150
mg twice daily for most patients, with a dose of 75 mg twice
daily recommended for patients with creatinine clearance
(CrCl) of 15 to 30 mL/min.69 The phase 3 Randomized Eval-
uation of Long-Term Anticoagulation Therapy (RE-LY) trial
compared open-label dose-adjusted warfarin with 2 blinded
doses (150 mg twice a day or 110 mg twice a day) of dabigatran
etexilate for the primary outcome of SSE in 18,113 patients
with NVAF.72,73 For warfarin-treated patients (n 5 6022), the
INR was within therapeutic range (2.0–3.0) a mean 64% of the
study period.72 Updated results adjudicated in a blinded fashion
according to the study protocol demonstrated that the dose of
150 mg twice daily of dabigatran etexilate was superior to
warfarin for the prevention of SSE (HR, 0.66; 95% CI, 0.53–
0.82; P , 0.001 for superiority), with a similar risk of the
primary safety end point of major bleeding (3.1% and 3.4%
per year, respectively; P 5 0.31).72,73 Lower rates of intracra-
nial hemorrhage were reported for dabigatran 110 mg twice
daily and 150 mg twice daily than for warfarin (0.2%, 0.3%,
and 0.7%, respectively; P , 0.001 for either dabigatran dose
versus warfarin).74 Similar rates of SSE were recorded in the
dabigatran etexilate 110 mg twice daily and warfarin groups
(1.54% and 1.71% a year, respectively; P 5 0.30); dabigatran
etexilate 110 mg twice daily was associated with a lower rate of
major bleeding than warfarin (2.9% versus 3.6% per year,
respectively; P 5 0.003).72,73 The FDA did not approve the
110 mg twice daily dose; hence, it is not available for clinical
use in the United States.53,69 The concomitant use of dabigatran
etexilate with P-glycoprotein (P-gp) inducers (eg, rifampin)
reduces exposure to dabigatran and should generally be
avoided.75 In patients with moderate renal impairment, concom-
itant administration of dabigatran etexilate with P-gp inhibitors
(eg, dronedarone and systemic ketoconazole) is not recommen-
ded, as coadministration is expected to increase exposure
to dabigatran.75 No drug–food interactions are reported.
Routine blood coagulation monitoring is not required during
dabigatran etexilate therapy, but when necessary, the extent
of anticoagulation may be estimated by measuring the activated
partial prothrombin time or the ecarin clotting time.75
Rivaroxaban
An oral factor Xa inhibitor, rivaroxaban, was approved
by the FDA in 2011 to reduce the risk of SSE in patients with
NVAF and subsequently for additional indications.10,70 To
reduce the risk of SSE in patients with NVAF, rivaroxaban is
administered at a dose of 20 mg/d to patients with CrCl $50
mL/min; for patients with CrCl 15 to 50 mL/min, the recom-
mended dose is 15 mg/d.10,75,76 Rivaroxaban and warfarin were
compared for efﬁcacy in 14,264 patients with NVAF in the
phase 3 Rivaroxaban Once-daily oral direct Factor Xa inhibi-
tion compared with vitamin K antagonism for the prevention of
stroke and Embolism Trial in AF (ROCKET-AF).76 The results
suggest that rivaroxaban may be an alternative to warfarin for
patients with AF with a moderate-to-high risk of stroke.32
Rivaroxaban was noninferior to warfarin for preventing SSE
both in the intent-to-treat population (2.1% and 2.4% a year,
respectively; P , 0.0001 for noninferiority) and the per-protocol
population (HR, 0.88; 95% CI, 0.74–1.03; P , 0.001 for
noninferiority and P 5 0.12 for superiority).76 Among patients
treated with warfarin, INR values were within therapeutic range
(2.0–3.0) for 55% of the time.76 The incidence of the primary
safety end point, major and clinically relevant nonmajor bleeding,
was similar in the rivaroxaban and warfarin groups (3.6% and
3.4%, respectively; P 5 0.44).76 The reported rate of intracranial
hemorrhage for rivaroxaban (0.5%) was lower than that for
warfarin (0.7%). Major GIB was more common in the rivarox-
aban group: 224 bleeding events (3.2%) compared with 154 in
the warfarin group (2.2%, P , 0.001).76 As with dabigatran,
routine blood coagulation monitoring is not required.75 Rivarox-
aban should not be used concurrently with other anticoagulants
or combined P-gp and strong cytochrome P450 3A4 (CYP3A4)
inhibitors and inducers.75
Apixaban
In 2012, this orally administered factor Xa inhibitor
received FDA approval to reduce the risk of SSE in patients
with NVAF.71 In clinical trials, apixaban was given as a ﬁxed
dose of 2.5 mg or 5 mg twice daily without routine coagulation
monitoring.32,77,78 The recommended dose is 5 mg twice daily;
for patients with $2 of the following characteristics: age, 80
years or older, body weight #60 kg and serum creatinine $1.5
mg/dL, the recommended dose is 2.5 mg twice daily.75 The
utility of apixaban for stroke prevention in NVAF was evalu-
ated in 2 large, randomized, double-blind trials: Apixaban for
Reduction in Stroke and Other Thromboembolic Events in
Atrial Fibrillation (ARISTOTLE)77 and Apixaban Versus Ace-
tylsalicylic Acid to Prevent Strokes (AVERROES).78 The
ARISTOTLE trial compared apixaban with warfarin for the
prevention of SSE in patients with NVAF and $1 additional
risk factor for stroke.77 Apixaban reduced SSE by 21% com-
pared with warfarin (HR, 0.79; 95% CI, 0.66–0.95; P 5
0.01).77 Apixaban treatment compared with warfarin resulted
in less major bleeding (2.1% and 3.1%, respectively; P ,
0.001) and intracranial hemorrhage (0.33% and 0.8%, respec-
tively). Apixaban was better tolerated than warfarin, and fewer
patients were withdrawn from therapy.77 In AVERROES, the
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efﬁcacy of apixaban 5 mg twice daily was compared with ASA
(81–325 mg once daily) for the prevention of SSE in 5,599
patients with NVAF who were not candidates for warfarin
treatment.78 The trial was stopped early on the recommendation
of the Data and Safety Monitoring Board when clear beneﬁts
favoring apixaban became evident regarding stroke reduction
(HR, 0.45; 95% CI, 0.32–0.62; P , 0.001).78 Rates of major
bleeding (1.4% versus 1.2%) and intracranial hemorrhage
(0.4% versus 0.4%) noted with apixaban were similar to those
observed with ASA. Apixaban was better tolerated than ASA,
with signiﬁcantly fewer discontinuations of study drug.78
Simultaneous use of strong inducers of CYP3A4 and P-gp
reduces blood levels of apixaban, and concurrent use should
be avoided.75 Concurrent use of an anticoagulant with an anti-
platelet agent or an NSAID generally increases bleeding risk,
and clopidogrel, in particular, should be used with caution if
coadministered with apixaban.75
CONCLUSIONS
Fear of bleeding is a widely acknowledged reason that
many physicians do not prescribe, and many patients at risk do
not receive, the requisite preventative anticoagulant therapy.
Although all anticoagulant therapies necessarily involve some
degree of bleeding risk, anticoagulation-related bleeding risk
may be lowered by consistent use of evidence-based stratiﬁca-
tion schemes designed to help physicians identify patients who
require anticoagulation to reduce the risk of stroke, predict the
risk of bleeding during anticoagulant therapy and take
preventive measures accordingly. Medication adherence may
be fostered with the use of one of the new ﬁxed-dose
anticoagulants rather than warfarin, which requires dose
adjustment and monitoring to maintain anticoagulant effect
within a narrow therapeutic window. Education plays a key role
in minimizing patient susceptibility, helping patients understand
the importance of lifelong anticoagulation and the need for
consistent lifestyle measures and raising awareness of signs and
symptoms of adverse events including bleeding. As more
evidence emerges from clinical trials, clinical guidelines may
be expected to converge and clarify optimal approaches to long-
term anticoagulant care.
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